Latest News and Press Releases

Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "CGT Research Outlook and Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report covers the...

Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Allogeneic Cell Therapies - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering Allogeneic cell therapies represent...

Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...

Burlingame, Feb. 24, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell therapy manufacturing market is estimated to be valued at US$ 3,755.4 million in 2022 and is...

Brooklyn, New York, Aug. 22, 2022 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Allogeneic Cell Therapy Market is projected to grow...

CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...

CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...

CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an...

RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply...